Navigation Links
Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
Date:5/24/2012

LEXINGTON, Ky. (May 24, 2012) David Feola, a University of Kentucky College of Pharmacy faculty member in the Department of Pharmacy Practice and Science, received a five-year, $1.8 million grant from the National Institutes of Health (NIH) to continue his research investigating immune responses in the lungs that will potentially lead to the discovery of medical treatments for patients with cystic fibrosis and other chronic pulmonary inflammatory conditions.

Cystic fibrosis is a life-threatening disease that causes mucus in the lungs to become too thick, which leads to severe pulmonary complications. This disease is one of the most common chronic lung diseases in children and young adults, affecting 30,000 children and adults in the United States and nearly 70,000 people worldwide, according to the Cystic Fibrosis Foundation.

Feola's research lab focuses on the regulatory function of macrophages, an immune cell type that kills invading pathogens and controls inflammation, in patients with chronic pulmonary inflammatory diseases. Cystic fibrosis causes progressive, life-threatening lung damage due in large part to repeated, dysregulated inflammatory responses to bacterial infection. Preliminary research in Feola's lab suggests that inducing specific types of macrophage activation could blunt this dysregulated inflammation. This research will lead to discovery of specific drug targets that could slow or halt this destructive cycle of inflammatory injury and pulmonary function decline in these patients.

"It is our hope that this research funding will provide us a greater understanding on how cystic fibrosis works, discover novel ways of treating the disease, and how we might be able to improve quality of life for these patients," said Feola, who also is a two-time graduate of the UK College of Pharmacy. Feola received his PharmD and PhD from the College.

Feola's grant is an investigator-initiated Research Project (R01) award, which is being funded by NIH's National Institute of Allergy and Infectious Diseases. R01 grant funding has become increasingly competitive due to the nation's current economic condition.

"The funding of this NIH grant is a testament to Dr. Feola's skill, expertise, tenacity and perseverance in pursing this support for his research program," said Linda Dwoskin, Associate Dean for Research for the UK College of Pharmacy. "I am extremely happy for him, his lab and the Pharmacy Practice and Science Department. I look forward to hearing about the great discoveries that result from Dr. Feola's research on cystic fibrosis."


'/>"/>

Contact: Allison Elliott
allison.elliott@uky.edu
University of Kentucky
Source:Eurekalert

Related medicine news :

1. McMaster University researchers discover drug destroys human cancer stem cells but not healthy ones
2. University studies and career expectations of medical students
3. University of Minnesota startup to treat challenging bacterial infection
4. Columbia University Medical Center and NY-Presbyterian experts at APA meeting
5. University of Houston Graduate College of Social Work announces partnership with MD Anderson
6. Neuropsychologist receives University of Houstons highest faculty honor
7. Louisiana Tech University professor earns NSF Early Career Development grant
8. Rice University student engineers automate limb lengthening for kids
9. Leading experts on congenital muscular dystrophy convene at University of Nevada, Reno
10. University of Cincinnati researchers win $3.7M grant from US Department of Defense
11. Oxford University Press partners with the Physical Society of Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... MALO, FRANCE (PRWEB) , ... January 21, 2017 , ... ... of the Indian Ocean, isolated from the rest of the world with ZANZIBAR SHOWER ... East Africa, Phytocéane used key ingredients, Virgin Coconut Oil and moisturizing vegetal coral to ...
(Date:1/21/2017)... ... January 21, 2017 , ... Northern California Medical Associates (NCMA) ... their multi-specialty medical group. The dermatology practice provides general dermatologic treatment, outpatient surgery, ... add this excellent dermatology practice to our group’s medical services,” explains NCMA CEO, ...
(Date:1/21/2017)... , ... January 21, 2017 , ... In the United ... individuals experience the freedom of recovery, they often feel shame for having struggled with ... stress disorder (PTSD). In the workshop, “Rising Strong in Life After an Eating Disorder” ...
(Date:1/20/2017)... ... ... ADA Portable Motion Trek BP 300 Lift. Built for durability, this pool lift is easy ... wheeled out of the way and stored when not in use. It is freestanding and ... from customers into specific enhancements and created a new product that is built directly on ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... bible in homes across the world. Yisrayl says this generation is a time like no ... to turn to the Bible. , Yisrayl says he does not want to sound like ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 Many patients don,t ... their medication when a pharmacy just a few blocks ...  To alleviate this problem Medicationdiscountcard.com has created ... see exactly how much their medication will cost at ... Easy Medicationdiscountcard.com takes ...
(Date:1/19/2017)... Jan. 19, 2017 Accuray Incorporated (Nasdaq: ... TomoTherapy® Systems continue to set the bar for excellence ... composite overall user satisfaction rating among radiation treatment delivery ... MD Buyline Market Intelligence Briefing™. The most recent ratings ... ratings among industry peers for 11 of the past ...
(Date:1/19/2017)... , Jan. 19, 2017 ViewRay, Inc. (Nasdaq: ... federal institution supporting research in Germany ... patient treatments at the University Clinic Heidelberg as part ... The MRIdian Linac program will be headed by Medical ... heads radiation oncology at the German Cancer Research Center ...
Breaking Medicine Technology: